Bittoni M et al. Real-world insights into patients with advanced NSCLC and MET alterations. Lung Cancer 2021;159:96-106. Abstract

Camidge DR et al. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: Final results of phase 3 ALTA-1L trial. J Thorac Oncol 2021;16(12):2091-108. Abstract

Camidge DR et al. Telisotuzumab vedotin (teliso-v) monotherapy in patients with previously treated c-Met⁺ advanced non-small cell lung cancer. IASLC 2021;Abstract OA15.04.

Cortot A et al. Safety of MET tyrosine kinase inhibitors in patients with MET exon 14 skipping non-small cell lung cancer: A clinical review. Clin Lung Cancer 2022;[Online ahead of print]. Abstract

Do KT et al. First-in-human, first-in-class, phase I trial of the fucosylation inhibitor SGN-2FF in patients with advanced solid tumors. Oncologist 2021;26(11):925-e1918. Abstract

Drilon A et al. Clinicopathologic features and response to therapy of NRG1 fusion-driven lung cancers: The eNRGy1 global multicenter registry. J Clin Oncol 2021;39(25):2791-802. Abstract

Dziadziuszko R et al. Circulating cell-free DNA as a prognostic biomarker in patients with advanced ALK+ non-small cell lung cancer in the global phase III ALEX trial. Clin Cancer Res 2022;[Online ahead of print]. Abstract

Goldman J et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met+ advanced non-small cell lung cancer: Stage 2. IASLC 2021;Abstract P47.03.

Mok T et al. Outcomes according to ALK status determined by central immunohistochemistry or fluorescence in situ hybridization in patients with ALK-positive NSCLC enrolled in the phase 3 ALEX study. J Thorac Oncol 2021;16(2):259-68. Abstract

Nardone V et al. Comparing addition of radiotherapy in EGFR- and ALK-positive NSCLC with brain metastases: Are we evaluating the optimal end point? J Thorac Oncol 2022;17(2):e10-2. Abstract

Stinchcombe TE et al. Short communication: The activity of brigatinib in patients with disease progression after next generation anaplastic lymphoma tyrosine kinase inhibitors and an exploratory analysis of circulating tumor DNA. Lung Cancer 2022;165:43-8. Abstract

Thomas NJ et al. Brain metastases in EGFR- and ALK-positive NSCLC: Outcomes of central nervous system-penetrant tyrosine kinase inhibitors alone versus in combination with radiation. J Thorac Oncol 2022;17(1):116-29. Abstract

Thomas NJ et al. In response to: “Comparing addition of radiotherapy in EGFR- and ALK-positive NSCLC with brain metastases: Are we evaluating the optimal endpoint?” J Thorac Oncol 2022;17(2):e12-4. Abstract

Tremblay G et al. Effectiveness of crizotinib versus entrectinib in ROS1-positive non-small-cell lung cancer using clinical and real-world data. Future Oncol 2022;[Online ahead of print]. Abstract

Tsui DCC et al. Central nervous system response to selpercartinib in patient with RET-rearranged non-small cell lung cancer after developing leptomeningeal disease on pralsetinib. Clin Lung Cancer 2022;23(1):e5-8. Abstract

Tsui DCC et al. Managing central nervous system spread of lung cancer: The state of the art. J Clin Oncol 2022;40(6):642-60. Abstract

Tsui DCC et al. Tumor shrinkage with combination of alectinib and trastuzumab in a patient with ALK-rearranged non-small cell lung cancer harboring HER2-amplification as an acquired resistance mechanism to ALK inhibitor therapy. Clin Lung Cancer 2022;23(2):e99-103. Abstract